Pratia joins Fortrea’s Site Network Partner program to propel healthcare innovation worldwide

Pratia, a leading Research Site Network, announces it has joined the Site Network Partner program of Fortrea, a global contract research organisation (CRO). This collaboration marks a significant milestone for Pratia, contributing to its mission of advancing health through cutting-edge clinical research.

Pratia operates a substantial Research Site Network comprising over 90 sites across seven countries in Europe making it the largest Site Network in Europe. Since its inception in 2012, Pratia has conducted more than 3000 clinical trials, establishing itself as a pioneer in delivering tech-savvy and adaptable solutions for innovative treatments. Joining Fortrea’s Site Network Partner program elevates Pratia’s capabilities and further strengthen its position as a key player in the delivery of clinical trials.

Today’s announcement underscores the shared commitment of Pratia and Fortrea to remove barriers and inefficiencies in starting, executing and completing clinical trials: As both organizations work more closely together, they aim to align processes to reduce complexity and accelerate the development of groundbreaking treatments, enhance patient outcomes, and contribute significantly to the evolution of global healthcare practices. 

“Fortrea recognizes the importance of a “listen first” approach to collaborating with all sites with whom we partner.  The expanding relationship with Pratia only further boosts this strategic alignment, collaboration and, ultimately, the combined ability to deliver high-quality trials for Patients and Sponsors,” said Mike Clay, Vice President, Development Strategy & Growth at Fortrea. 

“This strategic partnership is a culmination of our long and successful cooperation between Fortrea and Pratia and beginning of a new chapter moving forwards. We believe that new enhanced format will enable new synergies between our organization helping Pratia to continuously increase access to innovative treatments across various Patient populations in oncology and a broad range of therapeutic areas,” said Łukasz Bęczkowski, Chief Operating Officer at Pratia.